Abstract
It is generally accepted that active therapeutic immunization approaches hold great promise for treating malignant tumors. In recent years, lentiviral vectors have emerged as promising tools for anti-tumor immunotherapy due to their capacity to transduce a wide range of different dividing and non-dividing cell types, including tumor cells and dendritic cells (DC). The latter are considered to be the key regulators of immunity and are therefore applied as ‘nature’s adjuvant’ in terms of eliciting strong antigen-specific cytotoxic T lymphocyte responses against tumor antigens. Therefore, lentiviral vectors have been carefully examined as gene transfer vehicles, be it for ex vivo or in vivo modification of DC and have been demonstrated to induce potent T cell mediated immune responses that can control tumor growth. Here, we review the use of lentivirally transduced DC and lentiviral vectors - as such - as an anti-tumor immunotherapeutic. Furthermore, we focus on the DC modulatory capacity of lentiviral vectors and the various efforts that have been made to improve the overall performance and safety of in vivo administration of lentiviral vectors. In conclusion, this review highlights the potential of lentiviral vectors as a generally applicable ‘off-the-shelf’ therapeutic for anti-tumor immunotherapy.
Keywords: Lentivirus, antigen-presenting cell, dendritic cell, cytotoxic T cell, cancer, immunotherapy
Current Gene Therapy
Title: Lentiviral Vectors for Anti-Tumor Immunotherapy
Volume: 8 Issue: 6
Author(s): Karine Breckpot, Perpetua U. Emeagi and Kris Thielemans
Affiliation:
Keywords: Lentivirus, antigen-presenting cell, dendritic cell, cytotoxic T cell, cancer, immunotherapy
Abstract: It is generally accepted that active therapeutic immunization approaches hold great promise for treating malignant tumors. In recent years, lentiviral vectors have emerged as promising tools for anti-tumor immunotherapy due to their capacity to transduce a wide range of different dividing and non-dividing cell types, including tumor cells and dendritic cells (DC). The latter are considered to be the key regulators of immunity and are therefore applied as ‘nature’s adjuvant’ in terms of eliciting strong antigen-specific cytotoxic T lymphocyte responses against tumor antigens. Therefore, lentiviral vectors have been carefully examined as gene transfer vehicles, be it for ex vivo or in vivo modification of DC and have been demonstrated to induce potent T cell mediated immune responses that can control tumor growth. Here, we review the use of lentivirally transduced DC and lentiviral vectors - as such - as an anti-tumor immunotherapeutic. Furthermore, we focus on the DC modulatory capacity of lentiviral vectors and the various efforts that have been made to improve the overall performance and safety of in vivo administration of lentiviral vectors. In conclusion, this review highlights the potential of lentiviral vectors as a generally applicable ‘off-the-shelf’ therapeutic for anti-tumor immunotherapy.
Export Options
About this article
Cite this article as:
Breckpot Karine, Emeagi U. Perpetua and Thielemans Kris, Lentiviral Vectors for Anti-Tumor Immunotherapy, Current Gene Therapy 2008; 8 (6) . https://dx.doi.org/10.2174/156652308786848058
DOI https://dx.doi.org/10.2174/156652308786848058 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interleukin 2 in Cancer Therapy
Current Medicinal Chemistry Medicinal Compound Celastrol As a Potential Clinical Anticancer Drug: Lessons Learned From Preclinical Studies
Clinical Cancer Drugs Multiple Forms of Proteasomes and their Role in Tumor Fate
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) QSAR Studies on Blood-Brain Barrier Permeation
Current Computer-Aided Drug Design Marine Drugs: A Hidden Wealth and a New Epoch for Cancer Management
Current Drug Metabolism Chlorella vulgaris Induces Apoptosis of Human Non-Small Cell Lung Carcinoma (NSCLC) Cells
Medicinal Chemistry β-Carboline Alkaloids: Biochemical and Pharmacological Functions
Current Medicinal Chemistry Hepatocellular Carcinoma: Beyond the Boundaries of Age
Anti-Cancer Agents in Medicinal Chemistry Regulation of Arylamine N-Acetyltransferases
Current Drug Metabolism Nitric Oxide and Dietary Factors: Part IV Traditional Japanese Food (Soy Products, Fish and Tea)
Vascular Disease Prevention (Discontinued) Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy
Current Vascular Pharmacology Identification and Characterization of BRCA1 and BRCA2 Founder Mutations
Current Women`s Health Reviews Vitamin D Receptor Signaling and Pancreatic Cancer Cell EMT
Current Pharmaceutical Design The Emerging Landscapes to Drug Delivery Systems for the Treatment of Pancreatic Cancer
Current Medicinal Chemistry Characterization of Stem-Like Cells Directly Isolated from Freshly Resected Laryngeal Squamous Cell Carcinoma Specimens
Current Stem Cell Research & Therapy Aminophosphonic Acids of Potential Medical Importance
Current Medicinal Chemistry - Anti-Cancer Agents Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies
Current Pharmaceutical Design Role of Estradiol and Progesterone in HIV Susceptibility and Disease Progression
Mini-Reviews in Medicinal Chemistry Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
Current Cancer Drug Targets LASSBio-542: Novel Thalidomide Analog Distinctly Modulates IL-10 and Inhibits Angiogenesis
Current Bioactive Compounds